Aster Insights
Ben Bernstein is an accomplished Senior Product Manager with significant experience in product planning, execution, and management across various organizations. Currently at Aster Insights since November 2022, and previously at Sema4 from August 2021 to November 2022, Ben has developed expertise in user experience, data platforming, analytics, and operations automation. At ACUE, Ben led the complete buildout of technical product infrastructure and successfully scaled a certification program from 300 to over 25,000 users. Notable achievements include the creation of a student survey platform, automated credentialing system, and a multi-year data platform initiative. Ben's early career involved research at Northwestern University and NYU, focusing on cognitive science and spatial learning, with publications in peer-reviewed journals and presentations at notable conferences. Ben holds a Bachelor of Arts in Cognitive Science from Northwestern University.
This person is not in the org chart
This person is not in any offices
Aster Insights
We believe that personalized medicine starts with a complete view of an individual across their lifetime. Our company was founded in 2006 on the unique principle that informed consent from patients entrusting us with a lifetime connection to their health information, paired with deep partnerships across academia and the life sciences industry, would unlock critical advances in curing cancer. Aster Insights leads the Oncology Research Information Exchange Network (ORIEN®), a consortium of the nation’s leading academic cancer centers that conduct Total Cancer Care®, the world’s largest and longest running observational research study in oncology. TCC® serves as the foundation for novel insights that power oncology breakthroughs. As a long-time innovator in oncology, Aster Insights has world-class expertise in accelerating the life cycle of oncology medical product development. Our solutions are based on scientific and clinical intelligence and strengthened by our unique partnership with patients, academia, and industry. We empower our partners to uncover new targets and biomarkers, enhance cancer detection, deepen our understanding of new treatments, discover new indications, and accelerate clinical trials. Together, we are changing the way cancer is studied, treated, and prevented.